For the body to defend and fight against cancer, immune cells must recognize, engage, destroy and ultimately remove unwanted tumor cells. Understanding these processes at the cellular level is central to identifying and validating new immunotherapy approaches. Current methods for studying immune/tumor cell interactions are often end point, require cell lifting or measure indirect readouts meaning valuable data may be overlooked or compromised. In this webinar you will learn how continuous live-cell analysis enables a new range of non-invasive phenotypic measurements for immuno-oncology research including:
Tim O’Callaghan is Product Manager at Essen Bioscience where he works on the development of new and enabling live-cell analysis instruments, applications and reagents for oncology, immunology and neuroscience researchers. After completing an MSci in Biochemistry and Biological Chemistry at the University of Nottingham, Tim started his career developing in vitro cell-based assays to support high throughput screening and compound profiling drug discovery campaigns at GlaxoSmithKline and Pfizer. In 2009 Tim joined Essen BioScience where he has focussed on the field of continuous live-cell imaging and real-time phenotypic analysis.